MonoSol Rx to Present at 2015 American Association of Pharmaceutical Scientists Annual Exposition Demonstrating PharmFilm as a Bioequivalent Delivery Platform for Sildenafil Citrate

Company to Present Abstract Poster of Human Pilot Study Supporting PharmFilm® Bioavailability

Warren, N.J., October 21, 2015 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, today announced that the Company will present a poster supporting MonoSol Rx's PharmFilm® oral soluble film as a bioequivalent delivery method of Sildenafil Citrate (Viagra) at the 2015 AAPS Annual Meeting and Exposition in Orlando, Fl., October 25-29.

The author will present a data poster supporting findings from a pilot human clinical trial. The trial compared two formulations of Sildenafil Citrate as an oral soluble film (OSF) against the traditional tablet form.

Logistical details are listed below:

  • Abstract M1196: "Bioequivalence of Two Formulations of Sildenafil Oral Soluble Film 100 mg and Sildenafil Citrate (VIAGRA) 100 mg Oral Tables in Healthy Male Volunteers"
  • Date: October 26, 2015
  • Location: Exhibit Hall WB1-WB2

Keith Kendall, CEO of MonoSol Rx, commented "By providing patients an attractive alternative to everyday drugs using PharmFilm technology, we further demonstrate that MonoSol Rx is a specialty pharmaceutical company whose products are at the forefront of research, development, and innovation."

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.